-
Ironwood Pharmaceuticals (IRWD) PT Raised to $5 at Wells Fargo
-
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) to Market Outperform
-
Ironwood Pharmaceuticals issues 2026 financial guidance
-
VectivBio pays Ferring $12.5 million under amended license deal
-
Ironwood Pharma (IRWD) Tops Q3 EPS by 13c; offers guidance
-
FDA approves Ironwood's Linzess for pediatric IBS-C patients
-
Ironwood Pharma (IRWD) Tops Q2 EPS by 11c
-
Ironwood Pharma (IRWD) Misses Q1 EPS by 10c ; Offers Guidance
-
Ironwood Pharma (IRWD) Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
-
Craig-Hallum Downgrades Ironwood Pharmaceuticals (IRWD) to Hold
-
Wells Fargo Downgrades Ironwood Pharmaceuticals (IRWD) to Equal Weight
-
Jefferies Downgrades Ironwood Pharmaceuticals (IRWD) to Hold
-
Ironwood Pharmaceuticals (IRWD) PT Lowered to $1 at Leerink Partners
-
Ironwood Pharma (IRWD) Provides Clinical and Regulatory Update on Apraglutide
-
Ironwood Pharma (IRWD) Misses Q4 EPS by 4c, Misses on Revenue; Offers FY25 Revenue Guidance
-
Ironwood Pharma (IRWD) dropped from S&P 600
-
Millrose Properties (MRP) to Join S&P 600
-
Ironwood Pharmaceuticals (IRWD) PT Lowered to $14 at JMP Securities
-
Ironwood Pharma (IRWD) Initiates Apraglutide NDA Submission
-
Ironwood Pharma (IRWD) CFO to Resign
-
Ironwood Pharma (IRWD) Misses Q3 EPS by 5c ; Offers Guidance
-
Ironwood Pharma (IRWD): Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with SBS-IF
-
JMP Securities Reiterates Market Outperform Rating on Ironwood Pharmaceuticals (IRWD)
-
Leerink Partners Starts Ironwood Pharmaceuticals (IRWD) at Market Perform, 'overhang for shares'
-
Ironwood Pharma (IRWD) Misses Q2 EPS by 16c ; Offers Guidance

